NCEL — NewcelX Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1783036 ·
Switzerland
Last close
$3.11
Market Cap
$17.96M
52W High
$19.07
52W Low
$1.83
ADV30
6,153
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 9,700,000 | 710,000 | 3,659,000 |
| Dec 2025 | — | — | — | — | 11,445,000 | 2,201,000 | 4,195,000 |
| Jun 2025 | — | — | — | — | 459,252 | 297,893 | 15,487,801 |
| Dec 2024 | — | — | — | — | 903,000 | 650,000 | 8,899,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-84,891,000
Inventory
—
Receivables
$55,559
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -2,474,000 | -8,300,000 | 11,445,000 | 4,195,000 | 7,250,000 | -2,766,000 |
| Dec 2024 | 0 | -1,797,000 | -7,197,000 | 903,000 | 8,899,000 | -7,996,000 | -1,066,000 |
| Dec 2023 | 0 | -3,015,000 | -3,332,000 | 2,203,725 | 3,352,211 | -1,148,487 | -3,444,000 |
| Dec 2022 | 0 | -6,245,743 | -6,446,652 | 3,543,984 | 3,451,476 | 92,509 | -5,674,234 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.60
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NEUP | Neuphoria Therapeutics Inc. | $18.11M | $3.35 | — |
| INTI | Inhibitor Therapeutics, Inc. | $17.13M | $0.10 | — |
| PBM | PSYENCE BIOMEDICAL LTD. | $19.53M | $5.12 | — |
| ACTU | ACTUATE THERAPEUTICS, INC. | $16.31M | $0.68 | — |
| QNTM | Quantum Biopharma Ltd. | $20.00M | $3.11 | — |
News headlines (Yahoo Finance, 1h cache)
NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes
2026-09-28 12:00 · Yahoo
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
2026-07-31 13:00 · Yahoo
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
2026-07-01 13:30 · Yahoo
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
2026-06-15 12:30 · Yahoo
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
2026-05-27 11:55 · Yahoo
NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio
2026-07-15 13:00 · Yahoo
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
2026-07-08 13:15 · Yahoo
Despite NewcelX's Pullback, Insiders Still Gained ₪136k
2026-05-01 10:36 · Yahoo
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
2026-04-30 12:15 · Yahoo
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
2026-04-20 11:37 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.